ABCL
Abcellera Biologics Inc
12.80$
-2.4%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 0.0% | +39.2% | -7.2% | +45.4% | +141.1% | -16.6% | +2,120.8% | -2.5% | -86.4% | -80.1% | +2,429.6% | +127.2% | -85.5% | +120.8% | -78.7% | -43.4% | -17.5% | -34.4% | +39.1% | +8.4% | -26.4% | -11.1% | -22.4% | -16.1% | +303.4% | -47.6% | +400.9% | -81.5% | -51.3% | – | |
| – | 0.0% | +38.3% | +18.9% | +24.5% | +122.0% | -18.0% | +377.4% | -44.1% | -82.0% | +383.4% | +25.5% | +103.9% | -88.3% | +188.6% | -89.7% | +3,287.8% | -86.2% | +2.1% | +22.9% | -25.7% | +462.2% | +0.7% | -63.7% | +205.7% | -83.4% | – | – | +9.3% | – | – | |
| – | +0.0% | +42.9% | -115.9% | – | +141.1% | -16.6% | +2,120.8% | -12.1% | -86.8% | -77.1% | +2,032.1% | +131.6% | -85.0% | +112.1% | -76.8% | -39.0% | -17.5% | -34.4% | +39.1% | +8.4% | -26.4% | -11.1% | -22.4% | -16.1% | +303.4% | -47.6% | +312.4% | -100.9% | – | – | |
| – | 0.0% | +38.3% | +18.9% | +24.5% | +122.0% | -18.0% | +15.2% | +43.0% | +21.8% | +16.0% | -1.4% | +53.2% | +1.2% | -0.4% | +6.3% | +86.4% | -30.7% | +4.0% | +28.2% | -19.2% | +4.2% | +0.1% | +12.5% | -7.8% | -7.7% | +40.3% | -9.0% | -6.8% | -1.4% | – | |
| – | +0.0% | +31.3% | +38.7% | +69.2% | -9.2% | +98.1% | +95.2% | +10.8% | +74.4% | +0.6% | +14.4% | +10.7% | +1.0% | -4.3% | -5.6% | +16.3% | +2.6% | -7.4% | +11.2% | +8.6% | +16.4% | -5.2% | -16.3% | +1.3% | +17.0% | +16.2% | +159.6% | -78.5% | +12.3% | – | |
| – | +0.0% | -18.2% | +726.6% | +30.9% | +78.2% | -7.9% | +323.5% | -47.7% | +26.0% | +8.2% | +6.8% | +31.0% | +4.5% | -1.0% | +18.8% | +33.4% | -20.3% | +0.1% | +22.4% | -13.8% | +55.4% | -0.6% | -22.3% | -14.0% | -0.3% | +27.8% | -23.1% | -12.7% | +16.9% | – | |
| – | – | – | – | – | – | – | – | -1.7% | -104.4% | – | – | +175.8% | -103.7% | – | -200.1% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | +0.0% | – | – | – | -87.3% | -96.2% | +26,708.0% | +69.9% | +46.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -4,652.7% | – | – | -140.2% | – | +3.6% | -101.3% | – | – | +172.5% | -103.0% | – | -167.4% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | +11,721,285.5% | +13.8% | -99.4% | -1,536.8% | – | +151.3% | -100.2% | – | -107.6% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -4,652.7% | – | – | -140.2% | – | +0.2% | -102.0% | – | – | +181.2% | -104.0% | – | -212.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | -93.7% | +31,690.1% | +2.7% | -98.9% | -1,167.3% | – | +149.6% | -100.3% | – | -110.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.